Uterine cancer is curable in most cases, especially when caught early. The overall five-year survival rate across all stages is 84%, and for cancer that hasn’t spread beyond the uterus, that number climbs to 96%. The outlook depends heavily on when the cancer is found, what type it is, and how it responds to treatment.
Stage at Diagnosis Makes the Biggest Difference
The single most important factor in whether uterine cancer can be cured is how far it has spread at the time of diagnosis. Cancer that remains confined to the uterus (localized) has a five-year relative survival rate of about 95 to 96%. That means nearly all people diagnosed at this stage are alive five years later, at rates comparable to the general population. Most uterine cancers are caught at this stage because the most common early symptom, abnormal vaginal bleeding, tends to prompt a visit to a doctor relatively quickly.
When cancer has spread to nearby lymph nodes or tissues (regional disease), the five-year survival rate drops to around 70 to 72%. For cancer that has spread to distant organs like the lungs, liver, or bones, the rate falls to roughly 20 to 22%. These numbers reflect averages across many patients and don’t predict any individual outcome, but they illustrate how dramatically early detection shifts the odds.
Not All Uterine Cancers Behave the Same Way
The term “uterine cancer” covers several distinct diseases, and the type you have significantly affects curability. The most common form, called endometrioid carcinoma, accounts for the large majority of cases. It tends to be slower growing, more responsive to treatment, and more likely to be caught early. This is the type most associated with the favorable survival statistics above.
A smaller but more dangerous group includes serous carcinoma and clear cell carcinoma. Serous cancers make up less than 10% of all uterine cancers, yet they account for more than half of all recurrences and deaths from the disease. These aggressive subtypes are more common in older patients and are more likely to have spread beyond the uterus by the time they’re diagnosed. Even when caught at an early stage, they carry a higher risk of returning.
Uterine carcinosarcoma, a rare subtype that contains both carcinoma and sarcoma-like tissue, has an even worse prognosis. Compared to serous and clear cell cancers, carcinosarcoma carries a 1.5 to 1.6 times higher risk of death. These aggressive types often require more intensive treatment combinations.
How Early-Stage Uterine Cancer Is Treated
For cancer confined to the uterus, surgery is the primary treatment and is often curative on its own. The standard operation removes the uterus, fallopian tubes, and ovaries. For many patients with low-grade, early-stage disease, no additional treatment is needed after surgery. The cancer is simply gone.
Whether you need additional therapy after surgery depends on several factors that pathologists evaluate from the tissue removed during the operation: how deeply the cancer invaded the uterine wall, whether cancer cells were found in nearby blood or lymph vessels, the grade (how abnormal the cells look), and increasingly, the molecular profile of the tumor. The 2023 update to the international staging system now incorporates molecular markers into how uterine cancers are classified. Tumors with certain genetic changes (like a specific mutation called POLE) tend to have an excellent prognosis regardless of how they look under the microscope, while tumors with abnormal p53 protein are classified as higher risk and staged more aggressively.
Treatment for Advanced Disease
When uterine cancer has spread beyond the uterus, the goal of treatment shifts depending on how far it has traveled. Regional spread may still be treated with curative intent using a combination of surgery, radiation, and sometimes chemotherapy. Distant spread is harder to cure, but treatments have improved substantially in recent years.
One of the most significant advances has come from immunotherapy. About a quarter to a third of uterine cancers have a feature called mismatch repair deficiency, which means the tumor’s DNA repair system is broken. These tumors respond remarkably well to immune checkpoint drugs. In a major clinical trial of more than 800 participants, 74% of patients with this tumor feature who received immunotherapy alongside chemotherapy were alive without their cancer worsening at 12 months, compared to just 38% who received chemotherapy alone. A second trial showed similarly striking results: at 24 months, 61% of immunotherapy patients were progression-free versus only 16% on chemotherapy alone.
For the majority of advanced uterine cancers that don’t have mismatch repair deficiency, immunotherapy still offers some benefit when combined with chemotherapy, though the effect is less dramatic. Chemotherapy remains the backbone of treatment for widespread disease.
Recurrence: What to Watch For
Even after successful treatment, uterine cancer can come back. The risk of recurrence varies widely depending on the original stage and type. Low-grade, early-stage endometrioid cancers rarely recur, while aggressive subtypes like serous carcinoma have a recurrence rate that drives the majority of deaths from this disease.
After primary treatment, follow-up visits are typically scheduled every three to six months for the first two years, then every six months until the five-year mark. Most recurrences happen within the first three years. The symptoms most strongly linked to recurrence are vaginal bleeding, back or lower back pain, and persistent fatigue or exhaustion. Any of these symptoms between scheduled visits warrants contacting your care team rather than waiting for the next appointment.
Recurrent uterine cancer can sometimes still be treated successfully, particularly if it returns in a localized area like the top of the vagina, where radiation may be effective. Recurrence that shows up in distant organs is more difficult to treat but may respond to chemotherapy, immunotherapy, or targeted therapies depending on the tumor’s molecular characteristics.
Factors That Affect Your Individual Outlook
Population-level survival statistics are useful for understanding general patterns, but several personal factors shape your specific prognosis. The tumor’s molecular profile is becoming one of the most important. Tumors with POLE mutations tend to do well even when they look aggressive under a microscope. Tumors with p53 abnormalities tend to behave aggressively regardless of stage. Mismatch repair deficient tumors fall somewhere in between but respond exceptionally well to immunotherapy if they do progress.
Your age, overall health, and how completely the cancer can be removed surgically also matter. Younger patients generally have better outcomes, partly because they’re more likely to have the slower-growing endometrioid type and partly because they tend to tolerate treatment better. The completeness of surgery is particularly important for aggressive subtypes, where even small amounts of residual disease increase the chance of recurrence.
The bottom line is that the majority of people diagnosed with uterine cancer are cured. The disease is most treatable when found early, and the most common type carries the best prognosis. For those with advanced or aggressive forms, newer treatments, particularly immunotherapy, are meaningfully extending survival in ways that weren’t possible even five years ago.